| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/11/2009 | CN100467449C Cyclic aminophenyl sulfamate derivative |
| 03/11/2009 | CN100467073C Implants with a phosphazene-containing coating |
| 03/11/2009 | CN100467064C Application of imatinib and midostaurin in preparation of medicines for treating gastrointestinal stromal tumors |
| 03/11/2009 | CN100467061C Preparation method of scorpionfish-ink polysaccharide |
| 03/11/2009 | CN100467060C Intratumorally administered lactoferrin in the treatment of malignant neoplasms diseases |
| 03/11/2009 | CN100467059C Use of lactoferrin in the treatment of malignant neoplasms diseases |
| 03/11/2009 | CN100467045C Cancer treating medicine composition and its preparing method |
| 03/11/2009 | CN100467027C Combination product of inhibitor of the SRC family of non-receptor tyrosine kinases and gemcitabine |
| 03/11/2009 | CN100467023C Use of N-(3-methoxy-5-methyl pyrazine-2-group)-2-(4-[1,3,4-oxadiazole-2-group]phenyl) pyridine-3-sulfanilamide as anticarcinogen |
| 03/11/2009 | CN100467021C Novel 2-oxo-heterocyclic compounds, and use the pharmaceutical compositions comprising the same |
| 03/11/2009 | CA2716662A1 Polymer paclitaxel conjugates and methods for treating cancer |
| 03/11/2009 | CA2601558A1 Method of treating cancer by administration of 5-substituted nucleosides |
| 03/10/2009 | US7501516 3-Cyanoquinolines 4-substituted by a methylenedioxyphenyl group that is attached by a methylene, oxy, thio, sulfinyl, sulfonyl or amino group; antitumor agents |
| 03/10/2009 | US7501509 A tetrapyrollic photosensitizer compound having at least one pendant CH2CH2CON(CH2CON(CH2COOH)2)2 or N(CH2COOH)2 group, being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide |
| 03/10/2009 | US7501498 Moncolonal antibody for use in diagnosis and treatment of cell proliferative disorders; immunotherapy; tissue engineering |
| 03/10/2009 | US7501497 Comprising transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety and an immunoglobulin moiety comprising a heavy chain constant region of an immunoglobulin; interfere with binding of a tumor necrosis factor receptor with its ligand; antitumor agents |
| 03/10/2009 | US7501455 For parental injection of water insoluble drugs such as paclitaxel, propofol, amphotericin B, camptothecin, gemfibrozil and cyclosporin A; plasma protein such as serum albumin, an immunoglobulin, a glycoprotein, an interferon, or an interleukin, in controlled aggregation state |
| 03/10/2009 | US7501441 for treating uterine fibroid disease; [2-(4-hydroxyphenyl)-6-hydroxynaphthalen-1-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methane; therapy for post manupausal women |
| 03/10/2009 | US7501425 e.g. 1-Methyl-7-[4-(pyrazol-1-yl)phenylamino]pyrimido[4,5-d]pyrimidin-2(1H)-one; anticarcinogenic agents; restenosis, angiogenesis and atherosclerosis |
| 03/10/2009 | US7501417 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 03/10/2009 | US7501407 Amide substituted pyrimidine compound; antiarthritic agents; antiischemic agents; antidiabetic agents; inflammatory bowel disease; antiproliferative agents; antiallergens |
| 03/10/2009 | US7501399 Immunoeffector compounds |
| 03/10/2009 | US7501392 Method of treatment of viral hepatitis C with interferon alpha 5 |
| 03/10/2009 | US7501260 Methods for determining efficacy of chemotherapeutic agents for a patient prior to treatment |
| 03/10/2009 | US7501125 Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent |
| 03/10/2009 | CA2449856C Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
| 03/10/2009 | CA2363973C Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| 03/10/2009 | CA2358436C Polyunsaturated fatty acid derivatives and their use |
| 03/10/2009 | CA2352614C Lak activity-screening materials containing lentinus extract of edodes mycelium and lak activity-screening methods using the extract |
| 03/10/2009 | CA2347773C Certain substituted caprolactams, pharmaceutical compositions containing them and their use in treating tumors |
| 03/10/2009 | CA2345069C 2-phenylpyran-4-one derivatives |
| 03/10/2009 | CA2301057C A method of administering liposomal encapsulated taxane |
| 03/10/2009 | CA2197677C A method of selectively destroying neoplastic cells |
| 03/05/2009 | WO2009029844A1 Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods |
| 03/05/2009 | WO2009029609A1 Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 03/05/2009 | WO2009029069A1 Methods of inhibiting or suppressing cellular proliferation |
| 03/05/2009 | WO2009028972A1 A new inhibitor of dd-peptidase and its use as antibiotic or anticancer drug |
| 03/05/2009 | WO2009028968A1 Cell marker of melanocyte cell lineage and uses thereof |
| 03/05/2009 | WO2009028663A1 Anti-claudin-3 antibody |
| 03/05/2009 | WO2009028655A1 Heterocyclic compound and use thereof |
| 03/05/2009 | WO2009028639A1 Anti-epha2 antibody |
| 03/05/2009 | WO2009028629A1 Heterocyclic compound and use thereof |
| 03/05/2009 | WO2009028618A1 Piperidine derivative |
| 03/05/2009 | WO2009028581A1 Cancer-related genes, cdca5, epha7, stk31 and wdhd1 |
| 03/05/2009 | WO2009028580A1 Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis |
| 03/05/2009 | WO2009028559A1 Water-absorbing polymer particle and method for producing water-absorbing polymer particle |
| 03/05/2009 | WO2009028543A1 Substituted pyrazole derivative |
| 03/05/2009 | WO2009028521A1 Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis |
| 03/05/2009 | WO2009028411A1 Immunosuppression weaning agent comprising tumor cell and antitumor agent using the same |
| 03/05/2009 | WO2009028387A1 Therapeutic agent for cancer with resistance to protease inhibitor |
| 03/05/2009 | WO2009028319A1 Peptide derived from ephb6 mutant capable of binding to hla-a24 or hla-a2 molecule |
| 03/05/2009 | WO2009028158A1 Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| 03/05/2009 | WO2009028150A1 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent |
| 03/05/2009 | WO2009027994A2 NOVEL STEROIDAL ESTERS OF 17-OXIMINO-5-ANDROSTEN-3β-OL |
| 03/05/2009 | WO2009027746A1 Heterocyclic amides useful for the treatment of cancer and psoriasis |
| 03/05/2009 | WO2009027736A2 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer |
| 03/05/2009 | WO2009027706A2 Radiolabeled monomeric and multimeric cyclic oligopeptides binding to the cxcr4 receptor for cancer imaging and treatment |
| 03/05/2009 | WO2009027650A1 Materials and methods for exploiting synthetic lethality in brca-associated cancers |
| 03/05/2009 | WO2009027644A2 Compositions for the treatment of neoplastic diseases |
| 03/05/2009 | WO2009027641A2 Materials and methods for exploiting synthetic lethality in mismatch repair-deficient cancers |
| 03/05/2009 | WO2009027395A1 A new class of histone deacetylase inhibitors |
| 03/05/2009 | WO2009027392A1 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| 03/05/2009 | WO2009027264A1 Benzimidazole derivatives used as fxr agonists |
| 03/05/2009 | WO2009027076A1 Liquid formulation of g-csf |
| 03/05/2009 | WO2009026837A1 Derivatives of 4,5-disubstituted phenyl-3h-1,2-dithiole-3-thione, -one, -ketoxime and their use |
| 03/05/2009 | WO2009026723A1 Antigenic compositions and use of same in the targeted delivery of nucleic acids |
| 03/05/2009 | WO2009026717A1 Inhibitors of protein tyrosine kinase activity |
| 03/05/2009 | WO2009026701A1 Sirtuin inhibitors |
| 03/05/2009 | WO2009026692A1 An anti-cancer cytotoxic monoclonal antibody |
| 03/05/2009 | WO2009026681A1 Methods of inhibiting tumor growth using beta 5 integrin antagonists |
| 03/05/2009 | WO2009026658A1 Ppar agonists |
| 03/05/2009 | WO2009026657A1 Flavonoid ppar agonists |
| 03/05/2009 | WO2009012384A3 Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1 |
| 03/05/2009 | WO2009012382A3 Compositions, kits, and methods for the modulation of immune responses using galectin-1 |
| 03/05/2009 | WO2009010479A3 Heterocyclic methylene piperidine derivatives and their use |
| 03/05/2009 | WO2008157291A3 CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION |
| 03/05/2009 | WO2008153705A3 Methods of treating, diagnosing and detecting fgf21-associated disorders |
| 03/05/2009 | WO2008152392A3 Use of beta-gbp (galactoside binding protein) |
| 03/05/2009 | WO2008148849A8 Piperidine/piperazine derivatives |
| 03/05/2009 | WO2008142720A4 Quinazolin-oxime derivatives as hsp90 inhibitors |
| 03/05/2009 | WO2008138591A3 Bicyclic and heterobicyclic derivatives,processes for preparing them and their uses |
| 03/05/2009 | WO2008137622A3 Aminopyrimidines useful as kinase inhibitors |
| 03/05/2009 | WO2008110846A3 Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases |
| 03/05/2009 | WO2008024485A3 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent |
| 03/05/2009 | WO2007126365A8 Further medical uses of antisecretory protein |
| 03/05/2009 | US20090062785 Compositions and methods for cancer treatment using targeted single-walled carbon nanotubes |
| 03/05/2009 | US20090062401 Decaline-derived compounds as pharmaceutically active agents |
| 03/05/2009 | US20090062377 Anti-cancer combinations |
| 03/05/2009 | US20090062368 Deuterium-enriched sunitinib |
| 03/05/2009 | US20090062356 Substituted benzimidazole derivatives |
| 03/05/2009 | US20090062347 Deuterated axitinib (AG-13736), N-Methyl-2-[[3- [2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; cancer treatment |
| 03/05/2009 | US20090062343 Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 03/05/2009 | US20090062329 Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity |
| 03/05/2009 | US20090062328 Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods |
| 03/05/2009 | US20090062327 Inhibitors of AKT Activity |
| 03/05/2009 | US20090062326 M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors |
| 03/05/2009 | US20090062323 Deuterium-enriched irinotecan |
| 03/05/2009 | US20090062320 Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor |
| 03/05/2009 | US20090062318 Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
| 03/05/2009 | US20090062316 Deuterium-enriched pelitrexol |